These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 15832486)

  • 1. Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus.
    Göke B;
    Treat Endocrinol; 2002; 1(5):329-36. PubMed ID: 15832486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.
    Einhorn D; Rendell M; Rosenzweig J; Egan JW; Mathisen AL; Schneider RL
    Clin Ther; 2000 Dec; 22(12):1395-409. PubMed ID: 11192132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.
    Monami M; Vitale V; Ambrosio ML; Bartoli N; Toffanello G; Ragghianti B; Monami F; Marchionni N; Mannucci E
    Adv Ther; 2012 Sep; 29(9):736-46. PubMed ID: 22923161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin.
    Derosa G; Mereu R; D'Angelo A; Salvadeo SA; Ferrari I; Fogari E; Gravina A; Palumbo I; Maffioli P; Randazzo S; Cicero AF
    J Clin Pharm Ther; 2010 Oct; 35(5):565-79. PubMed ID: 20831680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
    Kipnes MS; Krosnick A; Rendell MS; Egan JW; Mathisen AL; Schneider RL
    Am J Med; 2001 Jul; 111(1):10-7. PubMed ID: 11448655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxisome proliferator-activated receptor-gamma agonist increases both low-density lipoprotein cholesterol particle size and small high-density lipoprotein cholesterol in patients with type 2 diabetes independent of diabetic control.
    Bavirti S; Ghanaat F; Tayek JA
    Endocr Pract; 2003; 9(6):487-93. PubMed ID: 14715475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Study of Effects of Pioglitazone and Rosiglitazone on Various Parameters in Patients of Type-2 Diabetes Mellitus with Special Reference to Lipid Profile.
    Sharma SK; Verma SH
    J Assoc Physicians India; 2016 Sep; 64(9):24-28. PubMed ID: 27762511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.
    Rosenstock J; Einhorn D; Hershon K; Glazer NB; Yu S;
    Int J Clin Pract; 2002 May; 56(4):251-7. PubMed ID: 12074206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial.
    Lewin AJ; Kipnes MS; Meneghini LF; Plotkin DJ; Perevozskaya IT; Shah S; Maccubbin DL; Mitchel YB; Tobert JA;
    Clin Ther; 2004 Mar; 26(3):379-89. PubMed ID: 15110130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
    Rosenblatt S; Miskin B; Glazer NB; Prince MJ; Robertson KE;
    Coron Artery Dis; 2001 Aug; 12(5):413-23. PubMed ID: 11491207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of pioglitazone hydrochloride on Japanese patients with type 2 diabetes mellitus.
    Teramoto T; Yamada N; Shirai K; Saito Y
    J Atheroscler Thromb; 2007 Apr; 14(2):86-93. PubMed ID: 17485893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
    Pfützner A; Schöndorf T; Tschöpe D; Lobmann R; Merke J; Müller J; Lehmann U; Fuchs W; Forst T
    Diabetes Technol Ther; 2011 Jun; 13(6):637-43. PubMed ID: 21457065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Six-month effectiveness and tolerability of pioglitazone in combination with sulfonylureas or metformin for the treatment of type 2 diabetes mellitus].
    Rodríguez A; Reviriego J; Polavieja P; Mesa J
    Med Clin (Barc); 2008 Nov; 131(19):721-30. PubMed ID: 19091199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of acarbose on glycemic control, serum lipids and lipoproteins in type 2 diabetes.
    Mughal MA; Memon MY; Zardari MK; Tanwani RK; Ali M
    J Pak Med Assoc; 2000 May; 50(5):152-6. PubMed ID: 11242714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records.
    Boyle PJ; King AB; Olansky L; Marchetti A; Lau H; Magar R; Martin J
    Clin Ther; 2002 Mar; 24(3):378-96. PubMed ID: 11952022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.
    Goldberg RB; Kendall DM; Deeg MA; Buse JB; Zagar AJ; Pinaire JA; Tan MH; Khan MA; Perez AT; Jacober SJ;
    Diabetes Care; 2005 Jul; 28(7):1547-54. PubMed ID: 15983299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.
    Schernthaner G; Matthews DR; Charbonnel B; Hanefeld M; Brunetti P;
    J Clin Endocrinol Metab; 2004 Dec; 89(12):6068-76. PubMed ID: 15579760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
    Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
    Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
    Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA
    Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of replacing metformin with pioglitazone on glycemic control in japanese patients with poorly controlled type 2 diabetes mellitus: A 12-week, open-label, prospective study.
    Sakaue S; Kamigaki M; Yoshimura H; Nishimura M
    Curr Ther Res Clin Exp; 2008 Aug; 69(4):364-77. PubMed ID: 24692813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.